Kameda, Takuro http://orcid.org/0000-0003-0100-1710
Shide, Kotaro
Kamiunten, Ayako
Kogure, Yasunori http://orcid.org/0000-0003-1158-5131
Morishita, Daisuke
Koya, Junji
Tahira, Yuki
Akizuki, Keiichi
Yokomizo-Nakano, Takako
Kubota, Sho
Marutsuka, Kosuke
Sekine, Masaaki
Hidaka, Tomonori
Kubuki, Yoko
Kitai, Yuichi
Matsuda, Tadashi
Yoda, Akinori
Ohshima, Takayuki http://orcid.org/0000-0002-1501-6430
Sugiyama, Midori
Sashida, Goro http://orcid.org/0000-0003-2318-5987
Kataoka, Keisuke
Ogawa, Seishi http://orcid.org/0000-0002-7778-5374
Shimoda, Kazuya http://orcid.org/0000-0002-2555-8188
Funding for this research was provided by:
Japan Agency for Medical Research and Development (20ck0106538h0001, 20ck0106409h0003)
MEXT | Japan Society for the Promotion of Science (17K09931)
Article History
Received: 19 January 2022
Accepted: 21 November 2022
First Online: 29 November 2022
Competing interests
: K. Shimoda has received consulting fees from Novartis Pharma, Takeda Pharmaceutical, Bristol-Myers, Shire Japan, and Celgene, all outside the submitted work, and has received research grants from Perseus Proteomics, Pharma Essentia Japan KK, AbbVie GK, Astellas Pharma, MSD, Chugai Pharmaceutical, Kyowa Kirin, Pfizer, Novartis Pharma, Otsuka Pharmaceutical, Asahi Kasei Medical, all outside the submitted work. K.K. holds stock in Asahi Genomics, has a patent for genetic alterations as a biomarker in T-cell lymphomas, and has received research funding from Chordia Therapeutics outside the submitted work. The remaining authors declare no competing interests.